Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.23 (
beta-galactosidase
)
14,648
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
G2E3
is a putative ubiquitin ligase (E3) identified in a microarray screen for mitotic regulatory proteins. It shuttles between the cytoplasm and nucleus, concentrating in nucleoli and relocalizing to the nucleoplasm in response to DNA damage. In this study, we demonstrate that
G2E3
is an unusual ubiquitin ligase that is essential in early embryonic development to prevent apoptotic death. This protein has a catalytically inactive HECT domain and two distinct RING-like ubiquitin ligase domains that catalyze lysine 48-linked polyubiquitination. To address in vivo function, we generated a knock-out mouse model of
G2E3
deficiency that incorporates a
beta-galactosidase
reporter gene under control of the endogenous promoter. Animals heterozygous for
G2E3
inactivation are phenotypically normal with no overt change in development, growth, longevity, or fertility, whereas
G2E3
null embryos die prior to implantation. Although normal numbers of
G2E3
(-/-) blastocysts are present at embryonic day 3.5, these blastocysts involute in culture as a result of massive apoptosis. Using
beta-galactosidase
staining as a marker for protein expression, we demonstrate that
G2E3
is predominantly expressed within the central nervous system and the early stages of limb bud formation of the developing embryo. In adult animals, the most intense staining is found in Purkinje cell bodies and cells lining the ductus deferens. In summary,
G2E3
is a dual function ubiquitin ligase essential for prevention of apoptosis in early embryogenesis.
...
PMID:G2E3 is a dual function ubiquitin ligase required for early embryonic development. 1851 20